Drug details

Eylea HD (aflibercept injection)

type of Macular Degeneration Agents, Ophthalmics, VEGF Inhibitors

Eylea HD (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).

This drug may have the following side effects:

• blurred vision,
• cataracts,
• increased intraocular pressure,
• bleeding in the eye,
• eye discomfort, pain, or irritation,
• eye “floaters,”
• vitreous detachment,
• corneal epithelium defect.

The following drugs are related to Eylea HD, either as a replacement or used together:

• Eylea (aflibercept)
• Avastin (bevacizumab)
• Beovu (brolucizumab-dbll for intravitreal injection)
• Vabysmo (faricimab-svoa injection)
• Lucentis (ranibizumab injection)